Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2009 4
2010 1
2011 3
2012 1
2013 2
2014 5
2015 3
2016 5
2017 4
2018 4
2019 1
2020 5
2021 5
2022 6
Text availability
Article attribute
Article type
Publication date

Search Results

45 results
Results by year
Filters applied: . Clear all
Page 1
Medication-Related Osteonecrosis of Jaws (MRONJ) Prevention and Diagnosis: Italian Consensus Update 2020.
Campisi G, Mauceri R, Bertoldo F, Bettini G, Biasotto M, Colella G, Consolo U, Di Fede O, Favia G, Fusco V, Gabriele M, Lo Casto A, Lo Muzio L, Marcianò A, Mascitti M, Meleti M, Mignogna MD, Oteri G, Panzarella V, Romeo U, Santarelli A, Vescovi P, Marchetti C, Bedogni A. Campisi G, et al. Among authors: fusco v. Int J Environ Res Public Health. 2020 Aug 18;17(16):5998. doi: 10.3390/ijerph17165998. Int J Environ Res Public Health. 2020. PMID: 32824826 Free PMC article.
Bedogni A, Fusco V, Di Fede O, Bettini G, Panzarella V, Mauceri R, Saia G, Campisi G. Bedogni A, et al. Among authors: fusco v. J Oral Maxillofac Surg. 2022 Jan;80(1):2-3. doi: 10.1016/j.joms.2021.09.021. Epub 2021 Oct 16. J Oral Maxillofac Surg. 2022. PMID: 34666036 No abstract available.
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F; GIM Investigators. De Placido S, et al. Lancet Oncol. 2018 Apr;19(4):474-485. doi: 10.1016/S1470-2045(18)30116-5. Epub 2018 Feb 23. Lancet Oncol. 2018. PMID: 29482983 Clinical Trial.
Adjuvant denosumab in early breast-cancer.
Fusco V, Campisi G, Bedogni A. Fusco V, et al. Lancet Oncol. 2020 Mar;21(3):e124. doi: 10.1016/S1470-2045(20)30066-8. Lancet Oncol. 2020. PMID: 32135108 No abstract available.
Is Medication-Related Osteonecrosis of the Jaws (MRONJ) Associated to Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors? A Word of Cautiousness. Comment on Marcianò et al. Medication-Related Osteonecrosis of the Jaws and CDK4/6 Inhibitors: A Recent Association. Int. J. Environ. Res. Public Health 2020, 17, 9509.
Fusco V, Alessio M, Guglielmini PF, Vincenti M, Fasciolo A, Rossi M. Fusco V, et al. Int J Environ Res Public Health. 2021 Sep 27;18(19):10143. doi: 10.3390/ijerph181910143. Int J Environ Res Public Health. 2021. PMID: 34639444 Free PMC article.
Persistence, compliance, discontinuation rates and switch rates in denosumab and bisphosphonate treatment of bone metastases in cancer patients: reasons of switch, osteonecrosis of the jaw (ONJ) and other critical points.
Rossi M, Gambino A, Cabras M, Alessio M, Fusco V. Rossi M, et al. Among authors: fusco v. Support Care Cancer. 2021 Aug;29(8):4185-4186. doi: 10.1007/s00520-021-06100-4. Epub 2021 Feb 25. Support Care Cancer. 2021. PMID: 33634351 No abstract available.
The Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Systematic Review with a Pooled Analysis of Only Surgery versus Combined Protocols.
Di Fede O, Canepa F, Panzarella V, Mauceri R, Del Gaizo C, Bedogni A, Fusco V, Tozzo P, Pizzo G, Campisi G, Galvano A. Di Fede O, et al. Among authors: fusco v. Int J Environ Res Public Health. 2021 Aug 10;18(16):8432. doi: 10.3390/ijerph18168432. Int J Environ Res Public Health. 2021. PMID: 34444181 Free PMC article.
45 results